Order Article Reprints

Kotfis K, Karolak I, Lechowicz K, Zegan-Barańska M, Pikulska A, Niedźwiedzka-Rystwej P, Kawa M, Sieńko J, Szylińska A, Wiśniewska M. Mineralocorticoid Receptor Antagonist (Potassium Canrenoate) Does Not Influence Outcome in the Treatment of COVID-19-Associated Pneumonia and Fibrosis—A Randomized Placebo Controlled Clinical Trial. Pharmaceuticals. 2022; 15(2):200. https://doi.org/10.3390/ph15020200

Kotfis, Katarzyna, Igor Karolak, Kacper Lechowicz, Małgorzata Zegan-Barańska, Agnieszka Pikulska, Paulina Niedźwiedzka-Rystwej, Miłosz Kawa, Jerzy Sieńko, Aleksandra Szylińska, and Magda Wiśniewska. 2022. "Mineralocorticoid Receptor Antagonist (Potassium Canrenoate) Does Not Influence Outcome in the Treatment of COVID-19-Associated Pneumonia and Fibrosis—A Randomized Placebo Controlled Clinical Trial" Pharmaceuticals 15, no. 2: 200. https://doi.org/10.3390/ph15020200

Kotfis, K., Karolak, I., Lechowicz, K., Zegan-Barańska, M., Pikulska, A., Niedźwiedzka-Rystwej, P., Kawa, M., Sieńko, J., Szylińska, A., & Wiśniewska, M. (2022). Mineralocorticoid Receptor Antagonist (Potassium Canrenoate) Does Not Influence Outcome in the Treatment of COVID-19-Associated Pneumonia and Fibrosis—A Randomized Placebo Controlled Clinical Trial. Pharmaceuticals, 15(2), 200. https://doi.org/10.3390/ph15020200